Cardiometabolic Candidate Endotypes in Psoriatic Disease: Integration of Clinical, Metabolic, and Immunogenetic Data

Rubén Queiro1,2,3, Paula Alvarez1, Ignacio Braña1

  • 1Rheumatology Division, Central University Hospital of Asturias, 33011 Oviedo, Spain.

Life (Basel, Switzerland)
|January 28, 2026
PubMed

Insights

Integrating the HLA-Cw6 gene marker into analyses of psoriatic disease (PsD) identified distinct cardiometabolic phenotypes. The study found opposite associations of HLA-Cw6 with high-risk profiles in psoriasis versus psoriatic arthritis, suggesting disease-specific implications.

Area of Science:

  • Immunogenetics
  • Cardiology
  • Rheumatology

Background:

  • Psoriatic disease (PsD), encompassing psoriasis (PsO) and psoriatic arthritis (PsA), presents heterogeneous cardiometabolic risks.
  • Integrating immunogenetic markers like HLA-Cw6 may refine PsD phenotyping and identify distinct endotypes.

Purpose of the Study:

  • To identify cardiometabolic phenotypes across PsD by integrating HLA-Cw6 data.
  • To explore disease-specific heterogeneity and predictors of high-risk profiles within PsD.

Main Methods:

  • A cross-sectional study involved 572 PsD patients, utilizing k-means clustering (k=4) with eight variables including HLA-Cw6.
  • Cardiometabolic risk factors were profiled, and cluster validity was assessed using Gaussian Mixture Models and PCA.
  • Stratified analyses for PsO and PsA were performed, with logistic regression examining predictors of high-risk phenotypes.

Main Results:

  • Four distinct cardiometabolic phenotypes were identified, including a high-risk subgroup (~6%) with older age, cardiovascular disease, hypertension, diabetes, and dyslipidemia.
  • High-risk phenotypes were observed in both PsO and PsA patient groups.
  • HLA-Cw6 showed opposing associations: enriched in high-risk PsO (OR 2.0) but depleted in high-risk PsA (OR 0.24).

Conclusions:

  • Clustering with HLA-Cw6 identified reproducible cardiometabolic phenotypes with unique genetic signatures.
  • Inverse HLA-Cw6 risk patterns in PsO and PsA suggest disease-specific cardiometabolic implications.
  • Longitudinal studies are warranted to validate these findings and their clinical implications.
Abstract

Related Concept Videos

Statistical Software for Data Analysis and Clinical Trials01:12

Statistical Software for Data Analysis and Clinical Trials

Statistical software is pivotal in data analysis and clinical trials by providing tools to analyze data, draw conclusions, and make predictions. These software packages range from simple data management applications to complex analytical platforms, supporting various statistical tests, models, and simulation techniques. Their significance lies in their ability to handle vast amounts of data with precision and efficiency, enabling researchers to validate hypotheses, identify trends, and make...
1.5K
Chronic Kidney Disease II: Clinical Manifestations01:24

Chronic Kidney Disease II: Clinical Manifestations

Chronic Kidney Disease (CKD) progressively impairs multiple body systems due to the accumulation of uremic toxins, which disrupt cellular functions across various organs.Neurologic symptomsNeurologic symptoms often arise early in CKD, as uremic toxin buildup drives changes in cognitive and motor functions. Patients frequently experience fatigue, headache, confusion, difficulty concentrating, and, in severe cases, seizures. Peripheral neuropathy commonly manifests as burning sensations in the...
617
What is Metabolism?00:52

What is Metabolism?

Overview
131.7K
Coronary Artery Disease III: Clinical Manifestations01:30

Coronary Artery Disease III: Clinical Manifestations

Coronary Artery Disease (CAD) is a primary health risk worldwide, leading to significant morbidity and mortality. The condition arises from the buildup of atherosclerotic plaques within the coronary arteries, resulting in diminished blood supply to the heart muscle.The clinical manifestations of CAD vary widely, from asymptomatic stages to severe, life-threatening conditions. Understanding these manifestations is crucial for early diagnosis and effective management.Angina Pectoris: The Warning...
364
Gastroesophageal Reflux Disease II: Clinical Features and Management01:29

Gastroesophageal Reflux Disease II: Clinical Features and Management

Gastroesophageal reflux disease, or GERD, is a persistent medical condition that affects many individuals worldwide. Its clinical manifestations can vary greatly, making diagnosis and management challenging for healthcare professionals. The following is a comprehensive overview of the clinical manifestations, assessment, and management strategies for GERD.
Clinical Manifestations
GERD presents itself in a multitude of ways, with symptoms varying from person to person. The hallmark symptoms are...
920
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies01:22

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
570